Azenta, Inc.
AZTA Healthcare Medical Instruments & Supplies
Azenta, Inc.’s revenue for fiscal 2025 (year ended September 2025) was $593.8 million, up 3.55% from fiscal 2024. In the quarter to June 2026, revenue grew 12.0%, EPS grew 104.4% and free cash flow fell 134.7%, each against the same quarter a year earlier. Dividend growth for ten consecutive years, revenue growth for three, operating cash flow growth for three; insiders bought in the last twelve months.
Follow AZTA
Azenta, Inc. (AZTA) EV/Sales
As of 16 October 2026, Azenta, Inc. (AZTA) trades at a EV/Sales of 2.1×. Over the past ten years it has ranged from 0.7× (May 2026) to 69.1× (September 2021); the current reading is higher than 26% of that period. That is below the Medical Instruments & Supplies industry median of 2.9× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 1.7× | (55.05%) |
| FY2024 | 3.8× | (9.31%) |
| FY2023 | 4.2× | 79.11% |
| FY2022 | 2.4× | (83.71%) |
| FY2021 | 14.5× | 75.32% |
| FY2020 | 8.2× | 15.67% |
| FY2019 | 7.1× | 88.94% |
| FY2018 | 3.8× | (4.24%) |
| FY2017 | 3.9× | 100.09% |
| FY2016 | 2.0× | 68.50% |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 1.4× | 33.15% |
| Mar 2026 | 1.1× | (45.19%) |
| Dec 2025 | 2.0× | 13.98% |
| Sep 2025 | 1.7× | (11.55%) |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| XRAY DENTSPLY SIRONA Inc. compare | 1.0× |
| NVST Envista Holdings Corporation compare | 1.4× |
| AZTA Azenta, Inc. | 2.1× |
| STAA STAAR Surgical Company compare | 2.7× |
| WRBY Warby Parker Inc. compare | 2.9× |
| ATRC AtriCure, Inc. compare | 4.7× |
| LMAT LeMaitre Vascular, Inc. compare | 6.3× |
| KMTS Kestra Medical Technologies, Ltd. compare | 13.8× |
| PLSE Pulse Biosciences, Inc compare | 2,555× |
| Medical Instruments & Supplies industry median | 2.9× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)